Compare Northrop Grumman Corporation (NOC) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Nuvalent Inc — how do they compare? Northrop Grumman Corporation trades at $510.06 (market cap $74.42B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Northrop Grumman Corporation is far larger — about 7.6× Nuvalent Inc's market cap, and Northrop Grumman Corporation pays a 1.79% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NOC | NUVL | |
|---|---|---|
Market Cap | $74.42B | $9.81B |
Sector | Industrials | Technology |
52-Week High | $768.02 | $123.96 |
52-Week Low | $496.02 | $72.16 |
Enterprise Value | $88.65B | $8.52B |
Dividend Yield | 1.79% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
